120 related articles for article (PubMed ID: 409419)
21. [The search for compounds with dopaminergic activity. VII. Synthesis of piribedil analogs].
Woliński J; Kujawa T; Prokopienko G; Rafalska B
Acta Pol Pharm; 1988; 45(3):206-9. PubMed ID: 3239429
[No Abstract] [Full Text] [Related]
22. Dopaminergic mechanisms in patients with extrapyramidal disease.
Chase TN; Shoulson I
Adv Neurol; 1975; 9():359-66. PubMed ID: 1146660
[No Abstract] [Full Text] [Related]
23. Brain dopamine turnover and the relief of parkinsonism.
Rinne UK; Sonninen V; Marttila R
Adv Exp Med Biol; 1977; 90():267-75. PubMed ID: 930747
[TBL] [Abstract][Full Text] [Related]
24. [Dopaminergic agonists in Parkinson disease].
Dubois B; Agid Y
Rev Prat; 1986 Jan; 36(5):207-14. PubMed ID: 3961400
[No Abstract] [Full Text] [Related]
25. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
Emre M; Rinne UK; Rascol A; Lees A; Agid Y; Lataste X
Mov Disord; 1992; 7(3):239-43. PubMed ID: 1535688
[TBL] [Abstract][Full Text] [Related]
26. Brain dopamine turnover and the relief of parkinsonism.
Rinne UK; Marttila R; Sonninen V
Arch Neurol; 1977 Oct; 34(10):626-9. PubMed ID: 907536
[TBL] [Abstract][Full Text] [Related]
27. Differentiation of apomorphine from bromocriptine, piribidel and TRH by chronic administration in rats.
Porreca F; Cowan A; Tallarida RJ
Psychopharmacology (Berl); 1982; 76(1):70-4. PubMed ID: 6805012
[No Abstract] [Full Text] [Related]
28. [Piribedil, dopaminergic agonist and the cerebral neurovascular syndrom of the aging man (author's transl)].
Babeau P; Pras P; Serizet A
Sem Hop; 1980 Jan 18-25; 56(3-4):188-92. PubMed ID: 6244655
[TBL] [Abstract][Full Text] [Related]
29. The effect of piribedil on body temperature in mice and rats.
Kapturkiewicz Z; Sowińska H
Pol J Pharmacol Pharm; 1977; 29(6):609-18. PubMed ID: 600860
[TBL] [Abstract][Full Text] [Related]
30. Piribedil--an oral dopamine agonist for treatment of Parkinson's disease.
Sweet RD; Wasterlain C; McDowell FH
Trans Am Neurol Assoc; 1974; 99():258-60. PubMed ID: 4463553
[No Abstract] [Full Text] [Related]
31. Actions of dopaminergic agonists in parkinsonism.
McDowell FH; Sweet R
Adv Neurol; 1975; 9():367-71. PubMed ID: 1096573
[No Abstract] [Full Text] [Related]
32. Piribedil: behavioural, neurochemical and clinical profile of a dopamine agonist.
Dourish CT
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(1):3-27. PubMed ID: 6304814
[No Abstract] [Full Text] [Related]
33. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
34. Protective effect of bromocriptine against BH4-induced Cath.a cell death involving up-regulation of antioxidant enzymes.
Lim JH; Kim SS; Boo DH; No H; Kang BY; Kim EM; Hwang O; Choi HJ
Neurosci Lett; 2009 Feb; 451(3):185-9. PubMed ID: 19146917
[TBL] [Abstract][Full Text] [Related]
35. [How do we explain the antihypertensive effect of bromocriptine? Clinical and experimental contribution].
Chamontin B; Montastruc JL; Rascol A
Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1181-5. PubMed ID: 6151826
[TBL] [Abstract][Full Text] [Related]
36. Dopaminephilic properties of ergot alkaloids.
Goldstein M; Lew JY; Nakamura S; Battista AF; Lieberman A; Fuxe K
Fed Proc; 1978 Jun; 37(8):2202-6. PubMed ID: 26607
[No Abstract] [Full Text] [Related]
37. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
[TBL] [Abstract][Full Text] [Related]
38. Piribedil therapy in Parkinson's disease. Use of the drug in the retard form.
Mentenopoulos G; Katsarou Z; Bostantjopoulou S; Logothetis J
Clin Neuropharmacol; 1989 Feb; 12(1):23-8. PubMed ID: 2713865
[TBL] [Abstract][Full Text] [Related]
39. Piribedil in Parkinson's syndrome: a clinical study.
Engel J; Granerus AK; Svanborg A
Eur J Clin Pharmacol; 1975 Apr; 8(3-4):223-6. PubMed ID: 183960
[TBL] [Abstract][Full Text] [Related]
40. The antiparkinsonian activity of dopamine agonists and their interaction with central dopamine receptor subtypes.
Goldstein M; Lieberman AN; Takasugi N; Shimizu Y; Kuga S
Adv Neurol; 1990; 53():101-6. PubMed ID: 1978511
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
